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PMC11
APPLICATION OF ZERO INFLATED POISSON MODEL FOR
ESTIMATING FUNCTIONS OF COST AND EFFECTIVENESS IN
COUNT DATA
Lee JH1, Kim CM2, Ock SM2, Choi WS2
1Korea University, Ansan, Kyunggi-do, South Korea, 2Catholic
University, Seoul, Suhcho-gu, South Korea
OBJECTIVES: In continuous outcome variables to be measures
of effectiveness in cost effectiveness/beneﬁt analysis, it is very
straightforward to estimate functions of cost and effectiveness
such as incremental cost effectiveness ratio(ICER), and incre-
mental net beneﬁt(INB). As well as life expectancy or survival
time, primary outcome variables in many clinical trials are count
data. Nevertheless, estimation or inference procedure of those
data is not well explained. Especially, measures of post treatment
in count data includes excessive zero due to treatment effect. In
this study, we provide and compare estimation strategies for
functions of cost and effectiveness which consist of counts using
Poisson, negative binomial, zero inﬂated Poisson model(includ-
ing regression model) and explore the properties of each model.
METHODS: Point and interval estimation of ICER and INB for
each model will be derived, and through the simulation study,
we compare power to assess the performance in various situa-
tions. Illustrative example was presented with “Randomised,
ﬂexible dose and open study to compare the efﬁcacy and safety
of Adalat Oros with ginkgo biloba extract to treat the patients
with the Raynaud’s disease”. RESULTS: On the ground of power
comparison and conﬁdence intervals of ICER and INB, ordinal
modeling of count data leaded to biased estimation of ICER and
INB. Compared to zero inﬂated Poisson model of ICER and INB,
simple estimation which count data were considered continuous
variable underestimated more than 1.5 times. CONCLUSION:
The study demonstrated the estimation procedure of cost and
effectiveness functions and appropriate modeling of count data
prevent biased estimate of ICER or INB.
PMC12
PRICE VS ACCESS:A PROBABILISTIC MODEL FOR GUIDING
PRICING DECISIONS
Muston D, Howard PA
Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK
OBJECTIVES: To produce a simple probabilistic model for
guiding pharmaceutical pricing decisions, across multiple and
various health care markets, in the presence of uncertainty
regarding market-speciﬁc characteristics, access and share.
METHODS: Pharmaceutical pricing appears to be largely deter-
mined by the price levels within a drug class or indication with
less emphasis placed on cost effectiveness and budgetary impact.
Health payers by contrast are increasingly using cost-effective-
ness and budgetary impact measures to determine whether a
product should be reimbursed at the requested price. We set out
a simple system for probabilistically modelling manufacturer rev-
enues from a product as a function of product price. The system
relies on explicit modelling of the reimbursement probability as
a function of price, and of market share conditional on reim-
bursement as a function of price. Uncertainty can be incorpo-
rated at the patient and market level. A revenue probability
distribution function is derived as a function of price. RESULTS:
For single market models, the system produces the familiar “all
or nothing” results of lesser interest: lower prices equate to
greater probabilities of reimbursement and market share. The
system is most valuable in multi-market situations where rela-
tionships are more complex or in markets where, due to the pres-
ence of competitor products or reference pricing, the relationship
with price of probability of acceptance or level of market share
is complex. Results in these settings are less generalizable. We
demonstrate this system in a number of illustrative single and
multi-market settings. CONCLUSION: The revenue probability
distribution function provides a useful tool to guide pharma-
ceutical pricing decisions, according to a company’s risk proﬁle.
The model developed facilitates decisions as to when and how
to trade-off reimbursement probability for revenue per patient,
with the aim of maximal revenues at a global level.
PMC13
JOINT DETERMINATION OF PRICES, RESEARCH
EXPENDITURE AND MARKETING EXPENDITURE BY
PHARMACEUTICAL FIRMS:A THEORETICAL MODEL OF
PROFIT-MAXIMIZING BEHAVIOR
Snyder S, King AE
Lehigh University, Bethlehem, PA, USA
OBJECTIVES: The activities of pharmaceutical companies in
developing, pricing and marketing their products continues to be
controversial, and literatures exist on each subject, but very little
has been published modeling their joint determination.
METHODS: Using standard micro-economic assumptions of
proﬁt-maximization we develop a model of the decision-making
process which yields an interior equilibrium, solve the model and
conduct comparative statics analyses. RESULTS: We ﬁnd strong
relationships between marketing and research expenditure. Mar-
keting and research are not substitutes, but complements. Exoge-
nous changes in the research environment which lead to an
increase in research will lead to a more than one-for-one increase
in marketing. Increasing shares of pharmaceutical costs paid
directly by consumers will lead to a decrease in marketing. CON-
CLUSION: Empirical studies of ﬁrm behavior may yield biased
results if they do not consider the simultaneous nature of the
ﬁrm’s decisions.
PMC14
PREDICTORS OF SELF-RATED HEALTH STATUS AMONG
GENERAL POPULATION IN THE UNITED STATES USING THE
MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Suh HS
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To investigate the predictors of self-rated health
status for the U.S. civilian noninstitutionalized population.
METHODS: Cross-sectional analyses using multivariate logistic
regression were performed with 11,405 individuals from the
2003 MEPS. The self-rated health status was dichotomized into
two categories (fair/poor health and good/very good/excellent
health). Standard demographic variables were employed as pre-
dictors in the regression, and the impact of a given predictor on
the self-rated health status was obtained as odds ratios. To check
the presence of multicollinearity, the conditional index and vari-
ance composition were examined. RESULTS: Smaller family size,
very low incomes (less than $15,000/year), non-white ethnicity
(Hispanic, African-American, and Asian), older ages, female,
lower education than college, having public health insurance,
and having worse mental health status were signiﬁcantly and
consistently associated with fair/poor perceived health (p < 0.05).
An additional family member and male gender were related with
decreased risk of fair/poor perceived health by 0.88 and 0.87,
respectively. Subjects with very low incomes, Hispanic ethnicity,
and aged between 56 to 65 were associated with 1.19, 1.34, 
and 3.65 times more likely to rate their health as fair/poor in
comparison with subjects with high incomes (more than
$100,000/year), White ethnicity, and aged between 16 to 25,
respectively. Similarly, persons with lower education (high school
degree) and public insurance would be 1.77 and 1.75 times as
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likely as persons with Bachelor’s degree and without insurance
to rate their health as fair/poor, respectively. An additional score
of mental health status (1 [excellent] ∼ 5 [poor]) was associated
with 2.67 times more likely to have fair/poor perceived health.
The model did not suffer from signiﬁcant multicollinearity since
the maximum conditional index was less than 10. CONCLU-
SION: Health perceptions are strongly associated with standard
demographic variables like income, ethnicity and age. Future
work should address the causal factors behind these associations.
PMC15
A RETROSPECTIVE ANALYSIS OF PATIENT-REPORTED
OUTCOMES AND OTHER EFFICACY ENDPOINTS IN TOP
BRAND NAME PRODUCT LABELS IN UNITED STATES
Varghese L, Lal L
Texas Southern University, Houston,TX, USA
OBJECTIVES: Patient-reported-outcomes (PROs) are endpoints
derived from the patient, collected by various means: verbally 
in a clinic, in a diary, event logs, symptom reports, or formal
instruments, to measure health status, compliance, and satisfac-
tion with treatment choices. This study determines the level of
PROs reported for the brand name drugs in the Top 200 Prod-
ucts in the US Total Market by Dispensed Total Scripts
(http://www.pharmacytimes.com), in comparison to other types
of effectiveness endpoints, such as clinician-reported-outcomes
(CROs) and laboratory values. METHODS: Brand name drugs
with web based package inserts from a list of the top 200 drugs
for 2005 were selected for inclusion in this study. Data collected
included: brand and generic names, manufacturer, therapeutic
class, and types and numbers of PROs, CROs, and laboratory
endpoints present in the package insert. RESULTS: Eighty-six
brand name drugs were included in the ﬁnal analysis, with the
highest percentages for antihypertensives and dyslipidemic
agents. Patient-reported-outcomes (PROs) were reported in 10
(11.63%) of the package inserts reviewed. Clinician-reported-
outcomes (CROs) were reported in 73 (84.88%) of the package
inserts reviewed and laboratory outcomes were reported in 23
(26.74%) of the package inserts. Twenty-three separate formal
PRO scales were utilized, with the most common ones present
in the package inserts of medications for depression, asthma, gas-
trointestinal and erectile dysfunctions. CONCLUSION: There
appears to be signiﬁcant amount of PROs and PRO instruments
that are utilized in the labeling information of the top brand
name products being sold in United States. Pharmacists and
other health care providers need to become familiar with the
formal scales and evaluation parameters of these PROs to be
effective decision makers.
PMC16
A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE
GENERAL PATIENT POPULATION IN FRANCE, GERMANY
AND UK
Bolge SC, Kannan H
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVES: To identify and describe differences in demo-
graphics, quality of life, resource utilization, and health care atti-
tudes between clinical trials participants and the general
population. METHODS: Data for this analysis were obtained
from the 2005 National Health and Wellness Survey (NHWS),
an annual nationally representative Internet-based study of the
health status, health care attitudes, and behaviors of adults (age
18+). The current analysis was limited to respondents from
France, Germany and the UK reporting a diagnosis of hyperten-
sion, high cholesterol, or diabetes (n = 8384). Respondents
reported ever participating in a clinical drug trial, demographic,
attitudes, resource use, and quality of life (SF-8 summary scores).
RESULTS: Across all countries, 6% (n = 472) reported ever par-
ticipating in a clinical drug trial (France, 4%; Germany, 6%; UK,
7%). In all countries, clinical trial participants were older
(France, 59.19 vs. 52.26, p < 0.01; Germany, 56.30 vs. 52.64, 
p < 0.01; UK, 59.93 vs. 56.01, p < 0.01), and had more frequent
physician visits (France, 9.17 vs. 1.01, p = 0.01; Germany, 10.27
vs. 7.47, p < 0.001; UK, 6.51 vs. 5.60, p = 0.03). Clinical trials
participants in France and Germany reported lower physical
quality of life (France, 42.98 vs. 45.91, p < 0.01; Germany, 41.97
vs. 44.11, p = 0.01) than the general population. Only trial par-
ticipants in Germany had lower mental quality of life (47.38 vs.
49.74, p < 0.01) and signiﬁcantly more emergency room visits
and hospitalizations. Trial participants in France were less likely
to have insurance than the general population (86.41% vs.
94.44%, p < 0.01). Clinical trial participants in the UK were
more likely than the general UK population to report a prefer-
ence for prescription vs. OTC medications (50.50 vs. 42.02, p =
0.02). CONCLUSION: Clinical trial participants are intrinsi-
cally different from the general population. This should be con-
sidered in the design and implementation of clinical trials and
the generalization of results to the population.
PMC17
PRINCIPAL COMPONENT ANALYSIS OF A PATIENT
SATISFACTION OF CARE SURVEY AND THE 
RELATIONSHIP BETWEEN PRINCIPAL COMPONENTS 
AND OVERALL SATISFACTION
Livengood K
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The purpose of this study was to perform a prin-
cipal component analysis of a patient satisfaction of care survey
to determine the components or categories of questions inde-
pendent of those created by the designers of the survey. Further,
the study was ultimately intended to determine the correlation
between the principal components and overall satisfaction.
METHODS: Principal component analysis of a patient satisfac-
tion of care survey and the relationship between principal com-
ponents and overall satisfaction were performed on a patient
satisfaction survey conducted in a large health care plan in the
western United States. Fifty-seven providers were surveyed
across 25–40 patients per provider. Survey categories included
questions on the patient’s appointment; the patient’s perception
of the provider’s ofﬁce, staff, and facility; and overall satisfac-
tion with their provider. Principal component analysis was con-
ducted via factor analysis, using varimax rotation to produce
orthogonalities between components. The relationship between
principal components and overall satisfaction was evaluated
using ordinary least squares regression. RESULTS: The principal
component analysis produced four components. The ﬁrst com-
ponent contained questions related to the patient’s appointment.
The second component contained questions related to the
provider’s ofﬁce, the third component contained questions
related to the provider’s staff, and the fourth component con-
tained questions related to the provider’s facility. Overall satis-
faction had a signiﬁcant relationship with the ﬁrst and second
principal components (p < 0.001 and p < 0.05, respectively). The
third and fourth components were not signiﬁcant. CONCLU-
SION: Patients are concerned with the following elements of care
from their providers in decreasing order of importance: 1. ele-
ments related to the patient’s appointment with their provider,
2. elements related to the patient’s perception of their provider’s
ofﬁce, 3. elements related to the patient’s perception of their
provider’s staff, and 4. elements related to the patient’s percep-
tion of their provider’s facility.
